Brind.
  1. The European Medicines Agency (EMA) has made a decision regarding the case-by-case use of a medicine.
  2. The European Medicines Agency (EMA) is evaluating experimental treatments that were developed in Japan.

Nuvation Bio Inc. observed therapeutic responses in trials and is conducting a Phase 2 J201 study in Japan for its drug Safusidenib.

1 report, 1 independent Updated Jul 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Nuvation Bio Inc. observed therapeutic responses in trials and is conducting a Phase 2 J201 study in Japan for its drug Safusidenib.

Keep exploring

Part of

The European Medicines Agency (EMA) is evaluating experimental treatments that were developed in Japan. All 1 developments

Within The European Medicines Agency (EMA) has made a decision regarding the case-by-case use of a medicine.

Coverage

Newest first; wire copies grouped